Trial Search Results

Monoclonal Antibody Therapy in Treating Patients With Advanced or Recurrent Lymphoma

RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.

PURPOSE: Phase I trial to study the effectiveness of monoclonal antibody therapy in treating patients who have advanced or recurrent lymphoma.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Collaborator: National Cancer Institute (NCI)

Stanford Investigator(s):

Intervention(s):

  • Biological: visilizumab

Phase:

Phase 1

Eligibility


DISEASE CHARACTERISTICS:

   - Histologically confirmed CD3+ T-cell lymphoma for which no standard curative therapy
   exists

      - Peripheral T-cell lymphoma

         - Recurrent and/or progressive disease after at least 1 prior therapy

      - Mycosis fungoides

         - Stage IB/IIA

            - Recurrent and/or progressive disease after at least 2 prior therapies

         - Stage IIB-IVB

            - Recurrent and/or progressive disease after at least 1 prior therapy

      - All other T-cell lymphomas

         - Recurrent and/or progressive disease after at least 1 prior therapy

   - Evaluable disease

      - Any nodal site or mass lesion at least 1.5 cm in longest axis on physical exam or
      CT scan

      - Skin lesions at least 1 cm in longest axis for cutaneous lymphoma

   - High numbers of circulating T-cells allowed

PATIENT CHARACTERISTICS:

Age:

   - 18 and over

Performance status:

   - ECOG 0-2

   - Karnofsky 50-100%

Life expectancy:

   - Not specified

Hematopoietic:

   - WBC at least 2,000/mm^3*

   - Absolute neutrophil count at least 1,000/mm^3*

   - Platelet count at least 75,000/mm^3* NOTE: * Unless due to lymphoma

Hepatic:

   - Bilirubin no greater than 2.0 times normal*

   - AST/ALT no greater than 2.5 times upper limit of normal*

   - Hepatitis B and C negative NOTE: * Unless due to lymphoma

Renal:

   - Not specified

Cardiovascular:

   - No symptomatic congestive heart failure

   - No unstable angina pectoris

   - No cardiac arrhythmia

Other:

   - No other uncontrolled illness

   - No ongoing or active infection

   - No other active malignancies except basal cell skin cancer or carcinoma in situ of the
   cervix

   - HIV-1 negative

   - Not pregnant or nursing

   - Negative pregnancy test

   - Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

   - See Disease Characteristics

Biologic therapy:

   - At least 60 days since prior humanized or chimeric antibody therapy

Chemotherapy:

   - At least 3 weeks since prior chemotherapy

Endocrine therapy:

   - Not specified

Radiotherapy:

   - At least 3 weeks since prior radiotherapy

Surgery:

   - Not specified

Other:

   - At least 30 days since prior investigational drugs or therapies

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Not Recruiting